Continuing our longstanding commitment to philanthropy and community impact, Keylin and our Joint Venture partner Kinstone Group, have made a $100,000 donation to the Mater Foundation to advance critical ovarian cancer research.
Mater treats nearly half of all women diagnosed with ovarian cancer in Queensland each year, providing the clinical capability and patient access needed to translate research into real-world treatments. This funding will help advance innovation at a critical stage of clinical translation — driving breakthroughs in early detection, targeted therapies, and improved quality of life for women now and in the future.
“Mater Foundation wishes to acknowledge the incredible generosity from Keylin and Kinstone and their leadership in supporting cancer research,” said Andrew Thomas, Mater Foundation Chief Executive Officer.
Keylin remains deeply committed to philanthropy and to making a meaningful contribution to initiatives that deliver pioneering research, world-class care, and better outcomes for Queenslanders.
Others can donate by heading to materfoundation.org.au
